In a groundbreaking study, researchers from Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center, and Memorial Sloan Kettering Cancer Center have developed an artificial intelligence-powered blood test that can predict cancer recurrence with remarkable sensitivity.
Published in Nature Medicine on June 14, the study reveals how a machine learning model was trained to detect circulating tumour DNA (ctDNA) with high accuracy. This method has shown success in lung cancer, melanoma, breast cancer, colorectal cancer, and even precancerous colorectal polyps.
